Crucial Medicines - ‘Compassion’ plea to cancer drug companies
A HSE taskforce is likely to decide by this Thursday whether or not to approve paying out for Nivolumab and Pembrolizumab.
Speaking to the media, Mr Harris said that as part of the last Budget, the Department of Public Expenditure and Reform had ruled that drugs above a certain threshold would have to be sanctioned by the Government.



